Oslo University Hospital (Rikshospitalet, Oslo universitetssykehus) announces the introduction of a bone-anchored prosthetics program with the OPRA™ Implant System.
The department of orthopedics at Rikshospitalet has announced that they will be introducing a bone-anchored prosthetics program to help amputees who have lost their arms and legs lead more active and productive lives.
In 2020, Newsweek rated Oslo University Hospital as number 26 in its list of the top hospitals worldwide Top 100 hospitals worldwide 2020. Spearheading the program at Rikshospitalet is Professor Magne Røkkum, Department of Orthopedics. Read more about the program (in Norwegian) here.
Professor Røkkum and the team at Rikshospitalet will begin treating both transhumeral (above-elbow) and transfemoral (below-knee) amputees with the OPRA™ Implant System this autumn.
Says Professor Røkkum “I am looking forward to supplementing our reconstructive treatment of extremities with osseointegrated prostheses.”
Maria Lopez, CEO at Integrum, shared the following “we are thrilled that the OPRA™ Implant System will be introduced at another of the world’s top hospitals, and that even more patients will be able to enjoy the benefits of the treatment and lead more active lives”.
For further information, please contact:
Maria Lopez, CEO
Cell. +46 (0) 708-46 10 69
Email: maria.lopez@integrum.se
Certified Adviser:
Erik Penser Bank AB
Tel. +46 (0) 8 463 8000
Email: certifiedadviser@penser.se
About Integrum
Integrum AB is a publicly-traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden, with a US subsidiary in San Francisco, CA. Since1990, osseointegration, the science behind the OPRA™ Implant System has been helping individuals with amputations towards an improved quality of life.
Thorough surgical experience gained over almost three decades, from more than 500 surgeries in 14 countries, has led to the development of Integrum’s system for bone-anchored prosthetics – a beneficial alternative to the traditionally used socket prosthesis. Integrum’s OPRA™ Implant System was first approved by the US Food and Drug Administration (FDA) in 2015 for use in the US under a Humanitarian Use Device (HUD) designation, which was reviewed through the Humanitarian Device Exemption (HDE) pathway, which limited the level of marketing and sales activities.
In December 2020, Integrum successfully completed the most stringent medical device regulatory procedure in the world, and based on the solid scientific data submitted, was granted a PMA by the FDA for the OPRA™ Implant System, which is the only technology approved for above-knee, bone-anchored prosthetics in the U.S. More information on the company, and its innovative solutions for amputees, can be found at www.integrum.se